Nebula Research & Development LLC Increases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Nebula Research & Development LLC lifted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 325.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,914 shares of the company's stock after acquiring an additional 58,844 shares during the quarter. Nebula Research & Development LLC owned 0.09% of Syndax Pharmaceuticals worth $1,017,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its position in Syndax Pharmaceuticals by 16.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 57,019 shares of the company's stock worth $754,000 after acquiring an additional 8,092 shares during the period. Hsbc Holdings PLC increased its holdings in Syndax Pharmaceuticals by 15.3% in the 4th quarter. Hsbc Holdings PLC now owns 50,747 shares of the company's stock worth $656,000 after acquiring an additional 6,741 shares in the last quarter. Stifel Financial Corp raised its position in shares of Syndax Pharmaceuticals by 120.8% during the 4th quarter. Stifel Financial Corp now owns 37,475 shares of the company's stock valued at $495,000 after purchasing an additional 20,499 shares during the period. Tower Research Capital LLC TRC grew its holdings in Syndax Pharmaceuticals by 179.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,190 shares of the company's stock valued at $240,000 after buying an additional 11,681 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Syndax Pharmaceuticals by 6.2% in the 4th quarter. MetLife Investment Management LLC now owns 50,515 shares of the company's stock worth $668,000 after purchasing an additional 2,961 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently issued reports on SNDX shares. Scotiabank decreased their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th. Citigroup reduced their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $36.20.

Syndax Pharmaceuticals Stock Up 3.3 %

Shares of NASDAQ:SNDX traded up $0.45 during midday trading on Wednesday, reaching $14.15. The company's stock had a trading volume of 3,028,860 shares, compared to its average volume of 1,605,195. The stock has a fifty day moving average of $13.00 and a 200 day moving average of $14.80. The firm has a market capitalization of $1.22 billion, a PE ratio of -3.90 and a beta of 1.28. Syndax Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The business had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. Sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is owned by corporate insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).